Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis | Zendy

Shiguo Liu | Zendy; Yue Fang | Zendy; Huiling Shen | Zendy; Wenlin Xu | Zendy; Hao Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis

Author(s) -

Shiguo Liu,

Yue Fang,

Huiling Shen,

Wenlin Xu,

Hao Li

Publication year - 2013

Publication title -

acta biochimica et biophysica sinica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 57

eISSN - 1745-7270

pISSN - 1672-9145

DOI - 10.1093/abbs/gmt075

Subject(s) - cisplatin , berberine , ovarian cancer , cancer research , apoptosis , microrna , cell growth , cancer cell , medicine , oncology , cancer , chemistry , chemotherapy , pharmacology , biochemistry , gene

Recent studies have shown that microRNA-21 (miR-21) contributes to tumor resistance to chemotherapy. Interestingly, we have found that berberine could inhibit miR-21 expression in several cancer cell lines. In this study, we investigated whether berberine could modulate the sensitivity of ovarian cancer cells to cisplatin and explored the mechanism. The cisplatin-resistant SKOV3 cells that were incubated with berberine combined with cisplatin had a signicantly lower survival than the cisplatin alone group and enhanced cisplatin-induced apoptosis. Berberine could inhibit miR-21 expression and function in ovarian cancer, as shown by an enhancement of its target PDCD4, an important tumor suppressor in ovarian cancer. The results suggested that berberine could modulate the sensitivity of cisplatin via regulating miR-21/PDCD4 axis in the ovarian cancer cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research